keyword
MENU ▼
Read by QxMD icon Read
search

Bevacizumab

keyword
https://www.readbyqxmd.com/read/28548650/aflibercept-in-age-related-macular-degeneration-evaluating-its-role-as-a-primary-therapeutic-option
#1
REVIEW
M Ashraf, A A R Souka
The recent VIEW studies have demonstrated the non-inferiority of monthly and bi-monthly aflibercept in the management of wet age related macular degeneration (AMD) compared with ranibizumab. However, the current data are limited mainly to fixed dosing regimens with few studies looking at flexible dosing regimens of aflibercept in wet AMD. In addition, recent data from the VIEW 96 week extension has shown that patients being shifted from fixed dosing regimens to PRN have shown a drop in visual acuity and increase in central macular thickness...
May 26, 2017: Eye
https://www.readbyqxmd.com/read/28548129/central-pathology-review-with-two-stage-quality-assurance-for-pathological-response-after-neoadjuvant-chemotherapy-in-the-artemis-trial
#2
Jeremy St John Thomas, Elena Provenzano, Louise Hiller, Janet Dunn, Clare Blenkinsop, Louise Grybowicz, Anne-Laure Vallier, Ioannis Gounaris, Jean Abraham, Luke Hughes-Davies, Karen McAdam, Stephen Chan, Rizvana Ahmad, Tamas Hickish, Stephen Houston, Daniel Rea, Carlos Caldas, John Ms Bartlett, David Allan Cameron, Richard Laurence Hayward, Helena Margaret Earl
The ARTemis Trial tested standard neoadjuvant chemotherapy±bevacizumab in the treatment of HER2-negative early breast cancer. We compare data from central pathology review with report review and also the reporting behavior of the two central pathologists. Eight hundred women with HER2-negative early invasive breast cancer were recruited. Response to chemotherapy was assessed from local pathology reports for pathological complete response in breast and axillary lymph nodes. Sections from the original core biopsy and surgical excision were centrally reviewed by one of two trial pathologists blinded to the local pathology reports...
May 26, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28546934/foveal-thickness-reduction-after-anti-vascular-endothelial-growth-factor-treatment-in-chronic-diabetic-macular-edema
#3
Gabriel Willmann, Antonio Brunno Nepomuceno, Katharina Messias, Leticia Barroso, Ingrid U Scott, André Messias, Rodrigo Jorge
AIM: To report foveal thickness reduction in eyes with resolution of macular edema and recovery of a foveal depression after one-year of anti-vascular endothelial growth factor (anti-VEGF) therapy for center-involving diabetic macular edema (DME). METHODS: Foveal thickness was assessed with optical coherence tomography to determine the central subfield foveal thickness (CSFT) and macular volume in 42 eyes with DME (CSFT>275 µm). Evaluations also included measurement of best-corrected visual acuity (BCVA), and were performed at baseline, and upon foveal depression recovery achieved after 12 monthly intravitreal injections of either 1...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28546521/phase-ii-study-of-induction-chemotherapy-with-docetaxel-capecitabine-and-cisplatin-plus-bevacizumab-for-initially-unresectable-gastric-cancer-with-invasion-of-adjacent-organs-or-paraaortic-lymph-node-metastasis
#4
Jwa Hoon Kim, Sook Ryun Park, Min-Hee Ryu, Baek-Yeol Ryoo, Kyu-Pyo Kim, Beom Su Kim, Moon-Won Yoo, Jeong Hwan Yook, Byung Sik Kim, Jihun Kim, Sun-Ju Byeon, Yoon-Koo Kang
Purpose: To evaluate the efficacy and safety of induction chemotherapy with docetaxel, capecitabine, and cisplatin (DXP) plus bevacizumab (BEV) on initially unresectable locally advanced gastric cancer (LAGC) or paraaortic lymph node (PAN) metastatic gastric cancer (GC). Materials and Methods: Patients with LAGC or unresectable PAN metastatic GC received 6 induction chemotherapy cycles (60 mg/m2 docetaxel intravenously [i.v.] on day 1, 937.5 mg/m2 capecitabine orally twice daily on days 1-14, 60 mg/m2 cisplatin i...
May 24, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28542671/folfoxiri-plus-bevacizumab-as-conversion-therapy-for-patients-with-initially-unresectable-metastatic-colorectal-cancer-a-systematic-review-and-pooled-analysis
#5
Gianluca Tomasello, Fausto Petrelli, Michele Ghidini, Alessandro Russo, Rodolfo Passalacqua, Sandro Barni
Importance: The combination of fluorouracil, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-Bev) is an established and effective first-line chemotherapy regimen for metastatic colorectal cancer. However, resection rates of metastases and overall survival with this schedule have never been systematically evaluated in published studies including, but not limited to, the TRIBE (TRIplet plus BEvacizumab) trial. Objective: To assess the clinical efficacy of FOLFOXIRI-Bev, including outcomes and rates of surgical conversions...
May 25, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28541960/clinical-features-of-treated-and-untreated-type-1-idiopathic-macular-telangiectasia-without-the-occurrence-of-secondary-choroidal-neovascularization-followed-for-2-years-in-japanese-patients
#6
Rie Osaka, Chieko Shiragami, Aoi Ono, Mamoru Kobayashi, Yukari Takasago, Ayana Yamashita, Akitaka Tsujikawa
PURPOSE: To evaluate the clinical features of Type 1 idiopathic macular telangiectasia (IMT) followed up for 2 years. METHODS: Forty-nine patients with unilateral Type 1 IMT were examined. Thirty-one IMT eyes were treated with direct laser photocoagulation and/or intravitreal bevacizumab; the remaining 18 eyes, with good vision or slight macular edema, were untreated. Changes in best-corrected visual acuity and central retinal thickness between baseline and 24 months after the initial visit were examined...
May 24, 2017: Retina
https://www.readbyqxmd.com/read/28541630/universal-tolerance-of-nab-paclitaxel-for-gynecologic-malignancies-in-patients-with-prior-taxane-hypersensitivity-reactions
#7
Kathryn Maurer, Chad Michener, Haider Mahdi, Peter G Rose
OBJECTIVE: To report on the incidence of nab-paclitaxel hypersensitivity reactions (HSRs) in patients with prior taxane HSR. METHODS: From 2005 to 2015, all patients who received nab-paclitaxel for a gynecologic malignancy were identified. Chart abstraction included pathology, prior therapy, indication for nab-paclitaxel, dosing, response, toxicities including any HSR, and reason for discontinuation of nab-paclitaxel therapy. RESULTS: We identified 37 patients with gynecologic malignancies with a history of paclitaxel HSR who received nab-paclitaxel...
July 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28539619/prognostic-importance-of-circulating-epidermal-growth-factor-like-domain-7-in-patients-with-metastatic-colorectal-cancer-treated-with-chemotherapy-and-bevacizumab
#8
Torben Frøstrup Hansen, Rikke Fredslund Andersen, Dorte Aalund Olsen, Flemming Brandt Sørensen, Anders Jakobsen
High tumor expression of epidermal growth factor-like domain 7 (EGFL7) has been associated with a poor prognosis in colorectal cancer. The aim of the current study was to investigate the possible prognostic impact of circulating EGFL7 (cir-EGFL7), combined with single nucleotide polymorphism (SNP) analyses, in patients with metastatic colorectal cancer (mCRC) treated with first line chemotherapy and bevacizumab. A total of 88 patients were included. Serum was collected prior to treatment initiation, at first evaluation after 3 weeks, and at progression...
May 24, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28536525/immune-checkpoint-in-glioblastoma-promising-and-challenging
#9
REVIEW
Jing Huang, Fangkun Liu, Zhixiong Liu, Hui Tang, Haishan Wu, Qianni Gong, Jindong Chen
Glioblastoma (GBM) is a severe malignant brain cancer with poor overall survival. Conventional intervention remains dismal to prevent recurrence and deterioration of GBM cell. Recent years have witnessed exciting breakthroughs in novel immune strategies, especially checkpoint inhibitors, some of which have become adjuvant setting after standard of care in melanoma. Several clinical trials of checkpoint inhibitors are ongoing in glioblastoma and other brain carcinomas. Plus, synergistic combinations of checkpoint inhibitors with conventional therapy strategies-radiotherapy, temozolomide, bevacizumab, and corticosteroids are now being exploited and applied in clinical settings...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28536391/glioma-fmiso-pet-mr-imaging-concurrent-with-antiangiogenic-therapy-molecular-imaging-as-a-clinical-tool-in-the-burgeoning-era-of-personalized-medicine
#10
Ramon F Barajas, Kenneth A Krohn, Jeanne M Link, Randall A Hawkins, Jennifer L Clarke, Miguel H Pampaloni, Soonmee Cha
The purpose of this article is to provide a focused overview of the current use of positron emission tomography (PET) molecular imaging in the burgeoning era of personalized medicine in the treatment of patients with glioma. Specifically, we demonstrate the utility of PET imaging as a tool for personalized diagnosis and therapy by highlighting a case series of four patients with recurrent high grade glioma who underwent 18F-fluoromisonidazole (FMISO) PET/MR (magnetic resonance) imaging through the course of antiangiogenic therapy...
October 31, 2016: Biomedicines
https://www.readbyqxmd.com/read/28536214/safe-administration-of-s-1-after-5-fluorouracil-induced-cardiotoxicity-in-a-patient-with-colorectal-cancer
#11
Caspar Franck, Peter Malfertheiner, Marino Venerito
Cardiotoxicity is a rare but challenging complication of 5-fluorouracil (5-FU) therapy. Compared with 5-FU, after application of S-1 lower plasma levels of the cardiotoxic metabolite alpha-fluoro-beta-alanine have been reported. Evidence for safe administration of S-1 following 5-FU cardiotoxicity is limited to a case report in an Asian patient. Herein we report the first case of S-1 application after 5-FU cardiotoxicity in a Caucasian patient.A 67-year-old man with right-sided metastatic colorectal cancer and history of 5-FU cardiotoxicity had a progressive disease after 8-month therapy with irinotecan and bevacizumab...
May 22, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28535756/switch-to-aflibercept-or-ranibizumab-after-initial-treatment-with-bevacizumab-in-eyes-with-neovascular-amd
#12
Maria Waizel, Margarita G Todorova, Michael Masyk, Katharina Wolf, Annekatrin Rickmann, Khaled Helaiwa, Björn R Blanke, Peter Szurman
BACKGROUND: To evaluate changes in central macular thickness (CMT) and visual outcome in patients with neovascular age-related macular degeneration (AMD) treated initially with bevacizumab and subsequently switched to either aflibercept or ranibizumab. METHODS: Observational clinical study was performed. We measured the structural outcome (CMT on SD-OCT; μm) and the visual outcome (best corrected visual acuity (BCVA); logMAR), as follows: before treatment (at baseline), following bevacizumab treatment (switch follow-up) and after switching from bevacizumab to aflibercept- or ranibizumab treatment (final follow-up, AG/, RG)...
May 23, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28535531/comparison-of-intravitreal-ranibizumab-aflibercept-and-dexamethasone-implant-after-bevacizumab-failure-in-macular-edema-secondary-to-retinal-vascular-occlusions
#13
Joel Hanhart, Yaacov Rozenman
PURPOSE: To compare the visual and anatomic outcomes of macular edema secondary to retinal vein occlusion after switching from bevacizumab to ranibizumab, aflibercept, or dexamethasone implant. METHODS: Fifteen eyes were switched to ranibizumab, 12 to aflibercept, and 10 to dexamethasone. At 3, 6, 9, and 12 months, the outcome measures were visual acuity (VA) and central macular thickness (CMT). RESULTS: One year after the switch, CMT decreased from 430...
May 24, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28534153/health-related-quality-of-life-outcomes-from-cabaret-a-randomized-phase-2-trial-of-carboplatin-and-bevacizumab-in-recurrent-glioblastoma
#14
Kathryn M Field, Madeleine T King, John Simes, David Espinoza, Elizabeth H Barnes, Kate Sawkins, Mark A Rosenthal, Lawrence Cher, Elizabeth Hovey, Helen Wheeler, Anna K Nowak
In recurrent glioblastoma, health-related quality of life (HRQL) is a crucial trial endpoint. We examined HRQL outcomes as a secondary endpoint for patients in the CABARET randomized phase 2 trial. 122 patients were randomly allocated to bevacizumab monotherapy or bevacizumab plus carboplatin. We calculated change scores from baseline for each HRQL measure on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and the Brain Cancer Module (QLQ-BN20), together with time to deterioration in HRQL, and the proportion of participants with clinically meaningful improvements in specific disease-related symptoms...
May 22, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28533089/synergistic-anti-tumor-effects-of-bevacizumab-and-tumor-targeted-polymerized-vegf-sirna-nanoparticles
#15
Myung Goo Kim, Sung Duk Jo, Ji Young Yhee, Beom Suk Lee, So Jin Lee, Sung Gurl Park, Sun-Woong Kang, Sun Hwa Kim, Ji Hoon Jeong
A variety of VEGF inhibitors have been reported to treat cancers by suppressing tumor angiogenesis. Bevacizumab, a monoclonal VEGF antibody, was the first FDA approved anti-angiogenic agent for cancer treatments. However, bevacizumab shows modest therapeutic efficiency and often cause resistant problem in significant populations of cancer patients. To solve these problem, we investigated the therapeutic efficacy of siRNA drugs targeting VEGF and combination of the RNAi drug with bevacizumab for cancer treatments...
May 19, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28531891/dual-inhibition-of-egfr-and-vegf-in-heavily-pretreated-patients-with-metastatic-colorectal-cancer
#16
Finn Ole Larsen, Alice Markussen, Dorte Nielsen, Bonnie Colville-Ebeling, Lene B Riis, Benny V Jensen
OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of combining irinotecan, bevacizumab, and cetuximab/panitumumab as a 4th-line treatment in patients with metastatic colorectal cancer. METHODS: All patients had KRAS wild-type metastatic colorectal cancer and had previously received fluoropyrimidine, oxaliplatin, irinotecan, and cetuximab/panitumumab in a 1st, 2nd, and 3rd line setting. Most patients had previously received bevacizumab as well...
May 23, 2017: Oncology
https://www.readbyqxmd.com/read/28527480/safety-and-effectiveness-of-cataract-surgery-with-simultaneous-intravitreal-anti-vegf-in-patients-with-previously-treated-exudative-age-related-macular-degeneration
#17
Manuel Sousa Falcão, Paulo Freitas-Costa, João Nuno Beato, João Pinheiro-Costa, Amândio Rocha-Sousa, Ângela Carneiro, Elisete Maria Brandão, Fernando Falcão-Reis
INTRODUCTION: To evaluate the safety and impact on visual acuity, retinal and choroidal morphology of simultaneous cataract surgery and intravitreal anti-vascular endothelial growth factor on patients with visually significant cataracts and previously treated exudative age-related macular degeneration. MATERIAL AND METHODS: Prospective study, which included 21 eyes of 20 patients with exudative age-related macular degeneration submitted to simultaneous phacoemulsification and intravitreal ranibizumab or bevacizumab...
February 27, 2017: Acta Médica Portuguesa
https://www.readbyqxmd.com/read/28527008/the-role-of-bevacizumab-in-the-treatment-of-glioblastoma
#18
REVIEW
Roberto Jose Diaz, Sheikh Ali, Mehreen Gull Qadir, Macarena I De La Fuente, Michael E Ivan, Ricardo J Komotar
Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in the United States for recurrent GBM in 2009. In order to review the therapeutic effect of bevacizumab in the primary and recurrent clinical setting we have performed a systematic analysis of data from the published literature. Weighted median progression free survival and overall survival were calculated and compared to standard therapy or other experimental therapies. A qualitative analysis of the limited studies on health related quality of life and effects on steroid requirements was also undertaken...
May 19, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28526907/a-prospective-study-of-xeliri-plus-bevacizumab-as-a-first-line-therapy-in-japanese-patients-with-unresectable-or-recurrent-colorectal-cancer-kscc1101
#19
Koji Ando, Yasunori Emi, Toyokuni Suenaga, Masahiro Hamanoue, Soichiro Maekawa, Yasuo Sakamoto, Seiichiro Kai, Hironaga Satake, Takayuki Shimose, Mototsugu Shimokawa, Hiroshi Saeki, Eiji Oki, Kenji Sakai, Yoshito Akagi, Hideo Baba, Yoshihiko Maehara
BACKGROUND: This study was designed to evaluate the efficacy and toxicity of XELIRI plus bevacizumab for the treatment of Japanese patients with unresectable or recurrent colorectal cancer (CRC). METHODS: This was a multicenter, single-arm, open-label prospective study. The major inclusion criteria were previously untreated unresectable or recurrent CRC, presence of measurable lesions, ≥20 years of age, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function...
May 19, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28521614/overcoming-platinum-resistance-in-ovarian-cancer-treatment-from-clinical-practice-to-emerging-chemical-therapies
#20
Federica Tomao, Claudia Marchetti, Alessia Romito, Anna Di Pinto, Violante Di Donato, Innocenza Palaia, Marco Monti, Ludovico Muzii, Pierluigi Benedetti Panici
The objective of this review is to summarize results from clinical trials that tested cytotoxic drugs and target strategies for the treatment of platinum resistant (PR) recurrent ovarian cancer (ROC) with particular attention to Phase III and ongoing trials. Areas covered: Since platinum free interval (PFI) represents the most important predictive factor for response to platinum re-treatment in ROC, non-platinum regimens are conventionally considered the most appropriate approaches. Impressive progress has been made in recent decades, resulting in the identification of most effective cytotoxic agents and in the development of new target strategies...
May 18, 2017: Expert Opinion on Pharmacotherapy
keyword
keyword
1763
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"